TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03584503

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suction Above Cuff Endotracheal Tube
Description: Suction Above Cuff Endotracheal Tube (SACETT) has a dorsal port above the cuff designed to allow continuous or intermittent suctioning of secretions from the subglottic space
Study: NCT01361373

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L- DOPA
Description: Sinemet up to 10 mg/kg/ day increasing gradually for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for 2 weeks
Study: NCT00975988

Intervention type: DRUG
Intervention: TYKERB® tablets
Description: Patients administrated TYKERB® tablets according to the prescribing information
Study: NCT00669903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0328

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05622448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RPD with PEEK framework
Description: removable partial denture with CAD designed PEEK framework

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RPD with PEEK framework
Description: removable partial denture with CAD designed PEEK framework

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RPD with metallic framework
Description: removable partial denture with cobalt chromium framework

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RPD with metallic framework
Description: removable partial denture with cobalt chromium framework
Study: NCT05822336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Duration of Intramuscular Injections
Description: This study was a single-group crossover clinical trial, where each participant acted as their own control. Two intramuscular injections into the right and left Dorsal Gluteal Region (DRG) were recorded for each participant. One was administered by a nurse, according to the unit's routine, and took 5 seconds to complete. A day after, the same nurse gave the other injection in the opposite DGR, taking 40 seconds to administer. The five-second injections were considered the control group, while the 40 seconds injections were the intervention group. The order of interventions was randomized. The pain level was determined and recorded immediately after each injection.
Study: NCT04069260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX-02
Description: ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).
Study: NCT01624649

Intervention type: DRUG
Intervention: Methylphenidate hydrochloride
Description: Form = tablet, route = oral, administered as a flexible dosage

Intervention type: DRUG
Intervention: Atomoxetine
Description: Form = tablet, route = oral;
Study: NCT02232841

Intervention type: DEVICE
Intervention: Mechanical Ventilation
Description: Subjects will receive mechanical ventilation as part of their standard of care, as specified in the enrollment criteria

Intervention type: DEVICE
Intervention: CT Scan
Description: Subjects will receive a CT scan as part of their standard of care, as specified in the enrollment criteria
Study: NCT01629680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxaverine
Description: Moxaverine-hydrochloride, coated tablets containing 150 mg moxaverine (Kollateral forte, Ursapharm. Saarbrücken, Germany), dosage: 900 mg, administrated per os in three equal doses of 300 mg at two hour intervals

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: coated tablets identical in number and appearance as the study drug
Study: NCT01121484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desvenlafaxine succinate sustained-release
Description: 50-mg DVS SR tablets taken orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablets taken orally once daily.
Study: NCT00997737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DB, VI and FI
Description: Two modalities of respiratory exercises based on deep and slow inspirations will be used: DB and IS. During DB, the researcher will place one hand slightly below the lower ribs in the abdominal region of the subject and the subject will be instructed to perform inspirations up to the maximum level of volume avoiding rib cage displacement; this recommendation will also be valid for exercises using incentive spirometers. IS will be executed using two different devices: Triflo II and Voldyne.
Study: NCT04396080

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial restoration in posterior teeth
Description: Teeth in need of onlays that will be treated with this type of treatment, choosing the most suitable material for each patient and following the manufacturer's instructions for their cementing and adhesion.
Study: NCT04803617

Intervention type: OTHER
Intervention: Assessment of pulmonary function and pectoralis muscle strength
Description: In both groups, forced vital capacity (FVC), forced expiratory volume in one second (FEV1) and FEV1 / FVC ratio were measured with portable spirometer according to the guidelines of the American Thoracic Society (ATS) and the European Respiratory Society (ERS). Maximal inspiratory (MIP) and expiratory pressure (MEP) were evaluated with mouth pressure device as per ATS/ERS guidelines. Sensation of dyspnea was assessed with Modified medical council research scale. Pectoralis muscle strength were measured isometrically using with digital hand held dynamometer.

Intervention type: OTHER
Intervention: Assessment of pulmonary function and pectoralis muscle strength
Description: In both groups, forced vital capacity (FVC), forced expiratory volume in one second (FEV1) and FEV1 / FVC ratio were measured with portable spirometer according to the guidelines of the American Thoracic Society (ATS) and the European Respiratory Society (ERS). Maximal inspiratory (MIP) and expiratory pressure (MEP) were evaluated with mouth pressure device as per ATS/ERS guidelines. Sensation of dyspnea was assessed with Modified medical council research scale. Pectoralis muscle strength were measured isometrically using with digital hand held dynamometer.
Study: NCT02712398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phasix™ ST
Description: Phasix™ ST is a fully resorbable mesh with a hydrogel coating that is also resorbable.
Study: NCT00699140

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGIV3I Grifols
Description: Immune Globulin Intravenous (Human)
Study: NCT02704897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wound Assessment Tool
Description: A set of questions relating to the symptoms of wound infection
Study: NCT02523521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity program
Description: physical activity program for a bronchopulmonary dysplasia children.
Study: NCT04306939

Intervention type: OTHER
Intervention: venipuncture
Description: Research blood collection is also an option via venipuncture if the subject is not scheduled for clinical testing. This will also be limited to 21cc of blood, up to 4 time a year, and with the approval of the attending physician.

Intervention type: OTHER
Intervention: venipuncture
Description: Research blood collection is also an option via venipuncture if the subject is not scheduled for clinical testing. This will also be limited to 21cc of blood, up to 4 time a year, and with the approval of the attending physician.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: PROMIS-43 Profile, PROMIS-29 Profile, Global Health Scale and Hospital Anxiety and Depression Scale (HADS). Additional assessments can be approved and administered per specific disease sub-category.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: PROMIS-43 Profile, PROMIS-29 Profile, Global Health Scale and Hospital Anxiety and Depression Scale (HADS). Additional assessments can be approved and administered per specific disease sub-category.
Study: NCT00449488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoetin alfa
Description: epoetin alfa 60.000 IU one i.v. bolus
Study: NCT00452985

Intervention type: DRUG
Intervention: Docetaxel
Description: 60-75 mg/m²

Intervention type: DRUG
Intervention: Carboplatin
Description: AUC 5
Study: NCT04792593

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Senl-h19 CAR-T
Description: Biological: Senl-h19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis
Study: NCT00956592

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CMAC video laryngoscope
Description: Intubation utilizing the assistance of video enhancement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope
Description: Patients will be intubated utilizing either a Macintosh 3 or Macintosh 4 designed blade
Study: NCT03214380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: Administered SC
Study: NCT04306939

Intervention type: OTHER
Intervention: Additional Sample Collections
Description: We may also contact subjects to request additional blood, saliva, cheek swab, hair, urine, or stool with their permission. This will be limited to no more than 4 teaspoons of blood and will happen no more than 4 times per year.

Intervention type: OTHER
Intervention: Additional Sample Collections
Description: We may also contact subjects to request additional blood, saliva, cheek swab, hair, urine, or stool with their permission. This will be limited to no more than 4 teaspoons of blood and will happen no more than 4 times per year.
Study: NCT02078505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet
Description: Carbohydrate poor diet
Study: NCT02812472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill training with functional electrical stimulation
Study: NCT03214380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2 inhibitor
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2 inhibitor
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Administered orally.
Study: NCT00256854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole IR 1 mg
Description: Ropinirole IR (SKF-101468) will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 1.0mg of active drug substance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole IR 1 mg
Description: Ropinirole IR (SKF-101468) will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 1.0mg of active drug substance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole IR 2 mg
Description: Ropinirole IR (SKF-101468) will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 2.0mg of active drug substance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole IR 2 mg
Description: Ropinirole IR (SKF-101468) will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 2.0mg of active drug substance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole IR 2 mg
Description: Ropinirole IR (SKF-101468) will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 2.0mg of active drug substance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole IR 2 mg
Description: Ropinirole IR (SKF-101468) will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 2.0mg of active drug substance.
Study: NCT03761134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT02812472

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training without functional electrical stimulation
Study: NCT00405405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: * Two cycles during neoadjuvant therapy~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: * Two cycles during neoadjuvant therapy~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: * Two cycles during neoadjuvant therapy~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: * Two cycles during neoadjuvant therapy (dose escalation)~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy begins as soon as possible following neoadjuvant chemotherapy, and continues for 7 weeks
Study: NCT00393523

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Modified Process Hepatitis B Vaccine
Description: Single dose 5 µg/0.5ml modified process hepatitis B vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Modified Process Hepatitis B Vaccine
Description: Single dose 5 µg/0.5ml modified process hepatitis B vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Modified Process Hepatitis B Vaccine
Description: Single dose 5 µg/0.5ml modified process hepatitis B vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Comparator: ENGERIX-B
Description: Single dose 10 µg/0.5ml ENGERIX-B

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Comparator: ENGERIX-B
Description: Single dose 10 µg/0.5ml ENGERIX-B
Study: NCT02650232

Intervention type: DEVICE
Group type: OTHER
Intervention: SOMNOtouch device (Somnomedics)
Description: In each arm, we will evaluate the capacity of SOMNOtouch to measure the baroreflex sensitivity compared to Finapre Nova (reference)

Intervention type: DEVICE
Group type: OTHER
Intervention: SOMNOtouch device (Somnomedics)
Description: In each arm, we will evaluate the capacity of SOMNOtouch to measure the baroreflex sensitivity compared to Finapre Nova (reference)

Intervention type: DEVICE
Group type: OTHER
Intervention: SOMNOtouch device (Somnomedics)
Description: In each arm, we will evaluate the capacity of SOMNOtouch to measure the baroreflex sensitivity compared to Finapre Nova (reference)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Orthostatic test
Description: For each arm we will proceed to an orthostatic test day one and day two with :~* 10 minutes in supine position~* 10 minutes in sitting position~* 5 minutes in standing position~* 5 minutes in supine position

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Orthostatic test
Description: For each arm we will proceed to an orthostatic test day one and day two with :~* 10 minutes in supine position~* 10 minutes in sitting position~* 5 minutes in standing position~* 5 minutes in supine position

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Orthostatic test
Description: For each arm we will proceed to an orthostatic test day one and day two with :~* 10 minutes in supine position~* 10 minutes in sitting position~* 5 minutes in standing position~* 5 minutes in supine position

Intervention type: DEVICE
Group type: OTHER
Intervention: Finapres Nova device (FMS system)

Intervention type: DEVICE
Group type: OTHER
Intervention: Finapres Nova device (FMS system)

Intervention type: DEVICE
Group type: OTHER
Intervention: Finapres Nova device (FMS system)
Study: NCT00227864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Study: NCT03282279

Intervention type: PROCEDURE
Intervention: TVOR
Description: Ultrasound guided transvaginal oocyte retrieval (TVOR) in deep sedation for IVF.
Study: NCT03973866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alfapump
Description: Implantation of alfapump
Study: NCT01992705

Intervention type: OTHER
Group type: OTHER
Intervention: Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable
Description: Patients will receive chemotherapy (21d/cycle for a total of 4 cycles) plus SBRT before screening for surgical resection of the pancreas.

Intervention type: DRUG
Group type: OTHER
Intervention: -Oxaliplatin 85 mg/m2 IV on Day 1
Description: Oxaliplatin 85 mg/m2 IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles).

Intervention type: DRUG
Group type: OTHER
Intervention: -Irinotecan 180 mg/m2 IV on Day 1
Description: Irinotecan 180 mg/m2 IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles).

Intervention type: DRUG
Group type: OTHER
Intervention: -5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours
Description: 5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours of each cycle (21d/cycle for a total of 4 cycles.
Study: NCT00640796

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haploidentical donor derived natural killer cell infusion
Description: Therapeutic cell infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Cyclophosphamide, Fludarabine, Interleukin-2, Mesna

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: Cell selection system based on magnetic-activated cell sorting
Study: NCT00744263

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: VACCINE: placebo
Description: 0.5 mL, single intra-muscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VACCINE: 13-valent pneumococcal conjugate vaccine
Description: 0.5 mL, single intra-muscular injection
Study: NCT02557490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin and raltitrexed
Description: TACE methods: use of epirubicin 20-40mg emulsifier lipiodol embolization target vessel, with gelatin sponge particles or PVA particles or microspheres embolization supplement.~Hepatic arterial chemotherapy: Bi embolization catheter in the hepatic artery or left hepatic artery branch within the right, chemotherapy, for the experimental group (A group): OXA 130mg / m2 artery 0-4 hours pumped Raltitrexed 3mg/m2 4-5 hours pumped into the arteries; the control group (group B)
Study: NCT02873819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GL-0817
Description: GL-0817, IV at the dose 1.5 mg will be administered 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hiltonol
Description: Hiltonol will be administered intramuscularly at the dose of 1.4 mg as adjuvant to GL0817, 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Sargramostim will be administered intramuscularly at the dose of 100 μg/m2, as adjuvant to GL0817, 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide will be administered IV at a dose of 200 mg/m2 (maximum dose 400 mg) one day prior to first three vaccinations of GL0817 with adjuvants

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (normal saline) will be administered as per the schedule of cyclophosphamide and GL0817/adjuvants administration
Study: NCT00875732

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi Ventricular Pacing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Right Ventricular Pacing
Study: NCT00288028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Dose of Bortezomib\* Level 1: 1.3 mg/m2 on Day 1, 4, 8, 11 - Every 21 days; Level 2: 1.3 mg/m2 on Day 1, 4, 8, 11 - Every 28 days; Level 3: 1.0 mg/m2 on Day 1, 8, 15 - Every 28 days; Level 4: 1.0 mg/m2 on Day 1, 8, 15 - Every 35 days
Study: NCT03761134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT01433484

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance of Weight Loss--Control
Description: As the maintenance of weight loss randomized trial does not begin until a year after the start of this study, the intervention and control conditions are not yet specified. This will occur before randomization and this section will be updated before the first participant is randomized.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maintenance of Weight Loss--Experimental